| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Invasive Fungal Infections | 5 | 2018 | 274 | 2.60 | Why? |
| Colistin | 3 | 2019 | 217 | 1.33 | Why? |
| Antibiotic Prophylaxis | 3 | 2018 | 399 | 1.22 | Why? |
| Triazoles | 3 | 2020 | 440 | 1.19 | Why? |
| Surgical Wound Infection | 4 | 2019 | 501 | 1.03 | Why? |
| Enterobacteriaceae Infections | 3 | 2018 | 529 | 0.97 | Why? |
| Antifungal Agents | 7 | 2020 | 1828 | 0.91 | Why? |
| Leukemia, Myeloid, Acute | 2 | 2018 | 676 | 0.88 | Why? |
| Anti-Bacterial Agents | 13 | 2019 | 10083 | 0.88 | Why? |
| Hospitals, Pediatric | 3 | 2021 | 1792 | 0.84 | Why? |
| Hematopoietic Stem Cell Transplantation | 8 | 2018 | 2426 | 0.78 | Why? |
| Abdominal Neoplasms | 1 | 2018 | 19 | 0.75 | Why? |
| Neutropenia | 2 | 2018 | 388 | 0.75 | Why? |
| Pseudomonas Infections | 3 | 2019 | 425 | 0.74 | Why? |
| Pelvic Neoplasms | 1 | 2018 | 25 | 0.73 | Why? |
| Cefazolin | 1 | 2018 | 31 | 0.73 | Why? |
| Pseudomonas aeruginosa | 3 | 2019 | 652 | 0.72 | Why? |
| Hepatic Veno-Occlusive Disease | 1 | 2017 | 25 | 0.72 | Why? |
| Sucrose | 1 | 2017 | 22 | 0.72 | Why? |
| Neurilemmoma | 1 | 2017 | 17 | 0.72 | Why? |
| Skin Diseases, Bacterial | 1 | 2019 | 105 | 0.70 | Why? |
| Enterobacter cloacae | 1 | 2017 | 58 | 0.70 | Why? |
| Leukemia | 2 | 2019 | 598 | 0.66 | Why? |
| Nitriles | 2 | 2020 | 1053 | 0.63 | Why? |
| Agammaglobulinemia | 1 | 2019 | 213 | 0.63 | Why? |
| Soft Tissue Neoplasms | 1 | 2017 | 131 | 0.62 | Why? |
| Genetic Diseases, X-Linked | 1 | 2019 | 237 | 0.62 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.61 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2018 | 398 | 0.61 | Why? |
| Drug Resistance, Multiple, Bacterial | 4 | 2018 | 1115 | 0.60 | Why? |
| Pyridines | 2 | 2020 | 680 | 0.59 | Why? |
| beta-Glucans | 1 | 2017 | 176 | 0.58 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2017 | 265 | 0.58 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.56 | Why? |
| Bacterial Infections | 2 | 2018 | 2229 | 0.54 | Why? |
| Gram-Negative Bacteria | 2 | 2018 | 473 | 0.53 | Why? |
| Child | 34 | 2021 | 70012 | 0.48 | Why? |
| Bacteremia | 3 | 2018 | 1372 | 0.43 | Why? |
| Pediatrics | 4 | 2021 | 2969 | 0.41 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 5002 | 0.40 | Why? |
| Child, Preschool | 23 | 2021 | 36283 | 0.39 | Why? |
| Infant | 18 | 2021 | 30274 | 0.37 | Why? |
| Immunocompromised Host | 4 | 2018 | 5150 | 0.36 | Why? |
| Intensive Care Units, Neonatal | 3 | 2019 | 749 | 0.34 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.32 | Why? |
| Cross Infection | 5 | 2019 | 8675 | 0.31 | Why? |
| Italy | 16 | 2021 | 38444 | 0.30 | Why? |
| Staphylococcal Infections | 4 | 2018 | 1099 | 0.30 | Why? |
| Neoplasms | 6 | 2020 | 17251 | 0.29 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2003 | 72 | 0.26 | Why? |
| Drug Utilization | 2 | 2017 | 619 | 0.24 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 1165 | 0.23 | Why? |
| Burkholderia cenocepacia | 1 | 2021 | 10 | 0.23 | Why? |
| Chromatography, High Pressure Liquid | 2 | 2017 | 669 | 0.22 | Why? |
| Burkholderia Infections | 1 | 2021 | 33 | 0.22 | Why? |
| Neuroaspergillosis | 1 | 2020 | 5 | 0.22 | Why? |
| Injections, Intravenous | 2 | 2021 | 381 | 0.21 | Why? |
| Fluconazole | 2 | 2019 | 145 | 0.21 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1573 | 0.21 | Why? |
| Tertiary Care Centers | 4 | 2019 | 8248 | 0.21 | Why? |
| Disease Transmission, Infectious | 2 | 2021 | 9044 | 0.21 | Why? |
| Bone Diseases | 1 | 2020 | 101 | 0.19 | Why? |
| Infant, Very Low Birth Weight | 1 | 2019 | 62 | 0.19 | Why? |
| Leg Ulcer | 1 | 2019 | 32 | 0.19 | Why? |
| Infant, Premature, Diseases | 1 | 2019 | 74 | 0.19 | Why? |
| Busulfan | 1 | 2018 | 22 | 0.19 | Why? |
| Adolescent | 18 | 2021 | 86841 | 0.19 | Why? |
| Humans | 53 | 2021 | 930598 | 0.18 | Why? |
| Negative-Pressure Wound Therapy | 1 | 2019 | 66 | 0.18 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.18 | Why? |
| Staphylococcus | 1 | 2018 | 77 | 0.18 | Why? |
| Catheterization, Central Venous | 1 | 2003 | 458 | 0.18 | Why? |
| Underage Drinking | 1 | 2018 | 30 | 0.17 | Why? |
| Thienamycins | 1 | 2017 | 72 | 0.17 | Why? |
| Drug Resistance, Fungal | 1 | 2019 | 191 | 0.17 | Why? |
| Administration, Intravenous | 2 | 2020 | 1115 | 0.17 | Why? |
| Neurotoxicity Syndromes | 1 | 2018 | 124 | 0.17 | Why? |
| Aspergillus | 1 | 2020 | 347 | 0.17 | Why? |
| Levofloxacin | 1 | 2017 | 115 | 0.17 | Why? |
| Graft vs Host Disease | 2 | 2018 | 501 | 0.16 | Why? |
| Administration, Topical | 1 | 2017 | 272 | 0.16 | Why? |
| Incidence | 6 | 2021 | 25622 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Infant, Newborn | 10 | 2021 | 23105 | 0.16 | Why? |
| Male | 28 | 2021 | 367725 | 0.16 | Why? |
| Rare Diseases | 1 | 2020 | 373 | 0.16 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.16 | Why? |
| Infant, Newborn, Diseases | 1 | 2020 | 394 | 0.16 | Why? |
| Osteomyelitis | 1 | 2018 | 131 | 0.16 | Why? |
| Transplantation, Autologous | 1 | 2017 | 364 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.15 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.15 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.15 | Why? |
| Hydrogen-Ion Concentration | 1 | 2019 | 993 | 0.15 | Why? |
| Tandem Mass Spectrometry | 3 | 2019 | 1031 | 0.14 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.14 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 711 | 0.14 | Why? |
| Stevens-Johnson Syndrome | 1 | 2017 | 129 | 0.14 | Why? |
| Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.14 | Why? |
| Candidiasis | 1 | 2019 | 334 | 0.14 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 526 | 0.14 | Why? |
| Candida | 1 | 2019 | 425 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.14 | Why? |
| Piperacillin | 1 | 2014 | 63 | 0.14 | Why? |
| Female | 29 | 2021 | 380317 | 0.14 | Why? |
| Ultrasonography, Interventional | 1 | 2019 | 560 | 0.13 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.13 | Why? |
| Penicillanic Acid | 1 | 2014 | 58 | 0.13 | Why? |
| Stem Cell Transplantation | 1 | 2019 | 531 | 0.13 | Why? |
| Fever | 2 | 2018 | 7795 | 0.13 | Why? |
| Area Under Curve | 2 | 2018 | 2564 | 0.13 | Why? |
| Cannula | 1 | 2019 | 750 | 0.13 | Why? |
| Wound Healing | 1 | 2017 | 424 | 0.13 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.13 | Why? |
| Post-Exposure Prophylaxis | 1 | 2018 | 472 | 0.13 | Why? |
| Cancer Survivors | 1 | 2020 | 588 | 0.13 | Why? |
| Dose-Response Relationship, Drug | 2 | 2018 | 3776 | 0.12 | Why? |
| Thoracic Surgery | 1 | 2019 | 623 | 0.11 | Why? |
| Intensive Care Units, Pediatric | 1 | 2018 | 1098 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.11 | Why? |
| Cystic Fibrosis | 1 | 2021 | 1104 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.11 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Clostridium Infections | 1 | 2017 | 595 | 0.10 | Why? |
| Chilblains | 1 | 2021 | 1156 | 0.10 | Why? |
| Medical Staff, Hospital | 1 | 2019 | 1258 | 0.10 | Why? |
| Drug Resistance, Multiple | 1 | 2010 | 156 | 0.09 | Why? |
| Hand Hygiene | 1 | 2019 | 1493 | 0.09 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.09 | Why? |
| Premature Birth | 1 | 2020 | 2151 | 0.09 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.09 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.09 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.09 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.08 | Why? |
| Plasma | 1 | 2017 | 1809 | 0.08 | Why? |
| Cardiac Surgical Procedures | 1 | 2019 | 1931 | 0.08 | Why? |
| Nursing Staff, Hospital | 1 | 2019 | 1554 | 0.07 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2019 | 2955 | 0.07 | Why? |
| Oxygen | 1 | 2019 | 3715 | 0.07 | Why? |
| Microbial Sensitivity Tests | 3 | 2019 | 2886 | 0.07 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Drug Administration Schedule | 2 | 2021 | 2324 | 0.07 | Why? |
| Glucocorticoids | 1 | 2021 | 4431 | 0.07 | Why? |
| Chromatography, Liquid | 2 | 2019 | 640 | 0.07 | Why? |
| Hospital Departments | 1 | 2012 | 831 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Drug Monitoring | 3 | 2019 | 1408 | 0.07 | Why? |
| Risk Management | 1 | 2012 | 1044 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.07 | Why? |
| Adult | 10 | 2021 | 244371 | 0.06 | Why? |
| Patient Outcome Assessment | 2 | 2017 | 707 | 0.06 | Why? |
| Chickenpox | 1 | 2005 | 194 | 0.06 | Why? |
| Catheters, Indwelling | 1 | 2003 | 84 | 0.06 | Why? |
| Dried Blood Spot Testing | 2 | 2017 | 383 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Sternum | 1 | 2019 | 30 | 0.05 | Why? |
| Infection Control | 2 | 2019 | 23131 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| X Chromosome | 1 | 1998 | 29 | 0.05 | Why? |
| Recurrence | 2 | 2021 | 3675 | 0.05 | Why? |
| Colony Count, Microbial | 1 | 2019 | 177 | 0.05 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.05 | Why? |
| Genetic Linkage | 1 | 1998 | 87 | 0.05 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.05 | Why? |
| Ribotyping | 1 | 2017 | 54 | 0.04 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.04 | Why? |
| Lymphoproliferative Disorders | 1 | 1998 | 110 | 0.04 | Why? |
| Causality | 1 | 2021 | 857 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Transplantation Conditioning | 1 | 2018 | 323 | 0.04 | Why? |
| Febrile Neutropenia | 1 | 2018 | 179 | 0.04 | Why? |
| Sepsis | 1 | 2013 | 3517 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.03 | Why? |
| Infant, Premature | 1 | 2019 | 883 | 0.03 | Why? |
| Freezing | 1 | 2014 | 106 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
| Nystatin | 1 | 2013 | 19 | 0.03 | Why? |
| Gestational Age | 1 | 2019 | 1488 | 0.03 | Why? |
| Plasmapheresis | 1 | 2017 | 437 | 0.03 | Why? |
| Drug Stability | 1 | 2014 | 236 | 0.03 | Why? |
| Contraindications | 1 | 2013 | 96 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Patient Compliance | 1 | 2003 | 1468 | 0.03 | Why? |
| Histamine H2 Antagonists | 1 | 2013 | 111 | 0.03 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.03 | Why? |
| Double-Blind Method | 1 | 2003 | 5988 | 0.03 | Why? |
| Hospitals, Public | 1 | 2017 | 774 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Staphylococcus aureus | 1 | 2017 | 844 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Lactoferrin | 1 | 2013 | 208 | 0.03 | Why? |
| Central Venous Catheters | 1 | 2013 | 188 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.03 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.02 | Why? |
| Pregnancy | 2 | 2020 | 23879 | 0.02 | Why? |
| Wounds and Injuries | 1 | 2020 | 1708 | 0.02 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.02 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.02 | Why? |
| Cerebellar Ataxia | 1 | 2005 | 78 | 0.02 | Why? |
| Probiotics | 1 | 2013 | 694 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.02 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2013 | 861 | 0.02 | Why? |
| Vasculitis, Central Nervous System | 1 | 2005 | 97 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2003 | 17020 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2017 | 3129 | 0.02 | Why? |
| Milk, Human | 1 | 2013 | 956 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2017 | 3099 | 0.02 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.02 | Why? |
| International Classification of Diseases | 1 | 2005 | 265 | 0.02 | Why? |
| Surgery Department, Hospital | 1 | 2012 | 954 | 0.01 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.01 | Why? |
| Anti-Infective Agents | 1 | 2013 | 1766 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Encephalitis | 1 | 2005 | 797 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.01 | Why? |
| Pedigree | 1 | 1998 | 502 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Middle Aged | 3 | 2021 | 270681 | 0.01 | Why? |
| Gene Deletion | 1 | 1998 | 430 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Cloning, Molecular | 1 | 1998 | 1036 | 0.01 | Why? |
| Haplotypes | 1 | 1998 | 853 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2010 | 3550 | 0.01 | Why? |
| DNA Primers | 1 | 1998 | 1170 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Base Sequence | 1 | 1998 | 3581 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |